(-)-OxypeucedaninCAS# 26091-73-6 |
- Oxypeucedanin
Catalog No.:BCN2494
CAS No.:737-52-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 26091-73-6 | SDF | Download SDF |
PubChem ID | 33306 | Appearance | Powder |
Formula | C16H14O5 | M.Wt | 286.3 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 4-[[(2S)-3,3-dimethyloxiran-2-yl]methoxy]furo[3,2-g]chromen-7-one | ||
SMILES | CC1(C(O1)COC2=C3C=CC(=O)OC3=CC4=C2C=CO4)C | ||
Standard InChIKey | QTAGQHZOLRFCBU-ZDUSSCGKSA-N | ||
Standard InChI | InChI=1S/C16H14O5/c1-16(2)13(21-16)8-19-15-9-3-4-14(17)20-12(9)7-11-10(15)5-6-18-11/h3-7,13H,8H2,1-2H3/t13-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
(-)-Oxypeucedanin Dilution Calculator
(-)-Oxypeucedanin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.4928 mL | 17.4642 mL | 34.9284 mL | 69.8568 mL | 87.321 mL |
5 mM | 0.6986 mL | 3.4928 mL | 6.9857 mL | 13.9714 mL | 17.4642 mL |
10 mM | 0.3493 mL | 1.7464 mL | 3.4928 mL | 6.9857 mL | 8.7321 mL |
50 mM | 0.0699 mL | 0.3493 mL | 0.6986 mL | 1.3971 mL | 1.7464 mL |
100 mM | 0.0349 mL | 0.1746 mL | 0.3493 mL | 0.6986 mL | 0.8732 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Myrciaphenone A
Catalog No.:BCN7003
CAS No.:26089-54-3
- Sotetsuflavone
Catalog No.:BCN3846
CAS No.:2608-21-1
- 3-Isomangostin hydrate
Catalog No.:BCN5134
CAS No.:26063-96-7
- 1-Isomangostin hydrate
Catalog No.:BCN5133
CAS No.:26063-95-6
- Boc-Asp(OBzl)-ONp
Catalog No.:BCC3364
CAS No.:26048-69-1
- Beauvericin
Catalog No.:BCC6546
CAS No.:26048-05-5
- PD173955
Catalog No.:BCC3999
CAS No.:260415-63-2
- Ligustroflavone
Catalog No.:BCN2370
CAS No.:260413-62-5
- Dihydroisotanshinone II
Catalog No.:BCN5132
CAS No.:260397-58-8
- Zamanic acid
Catalog No.:BCN5131
CAS No.:260393-05-3
- GI 254023X
Catalog No.:BCC2374
CAS No.:260264-93-5
- Xylose
Catalog No.:BCC4880
CAS No.:25990-60-7
- Byakangelicol
Catalog No.:BCN5015
CAS No.:26091-79-2
- AMC
Catalog No.:BCC2837
CAS No.:26093-31-2
- Otilonium Bromide
Catalog No.:BCC4573
CAS No.:26095-59-0
- Reneilmol
Catalog No.:BCN5135
CAS No.:260968-11-4
- Chicago Sky Blue 6B
Catalog No.:BCC6816
CAS No.:2610-05-1
- Cyanidin-3,5-O-diglucoside chloride
Catalog No.:BCN3116
CAS No.:2611-67-8
- Rhodojaponin II
Catalog No.:BCN2810
CAS No.:26116-89-2
- Picrasin B
Catalog No.:BCN5136
CAS No.:26121-56-2
- Madurensine
Catalog No.:BCN2092
CAS No.:26126-78-3
- 4-O-Feruloylquinic acid
Catalog No.:BCN3352
CAS No.:2613-86-7
- Frentizole
Catalog No.:BCC4035
CAS No.:26130-02-9
- Antiarol rutinoside
Catalog No.:BCN5137
CAS No.:261351-23-9
Reversal Effect of Oxypeucedanin on P-glycoprotein-mediated Drug Transport.[Pubmed:30042338]
Molecules. 2018 Jul 24;23(8). pii: molecules23081841.
P-glycoprotein affects the transport of numerous drugs including chemotherapeutic drugs vincristine sulfate (VCR) and docetaxel (DTX), and is one of the main causes for multidrug resistance. Our previous studies have shown that oxypeucedanin (OPD) can enhance the intestinal transit of puerarin and VCR. However, the underlying mechanism is unclear. This study investigated the potential mechanism by which OPD improves P-gp-mediated drug transport. Molecular docking was performed to predict the binding force between OPD and P-gp and the contribution of OPD on P-gp activity. We observed the effect of OPD on the transport of VCR in MDCK-MDR1 cell monolayer and also measured the plasma pharmacokinetic parameters of DTX in the presence and absence of OPD by LC-MS/MS. Moreover, we further investigated the reversal mechanism of OPD on P-gp-mediated drug transport by determining the intracellular accumulation of Rhodamine-123 (Rh123) and P-gp ATPase activity as well as protein expression and mRNA level of P-gp. Our molecular docking results revealed that the binding force between OPD and P-gp was much lower than that between P-gp and verapamil (a P-gp substrate). The transport study in vitro indicated that OPD increased the flux of VCR across MDCK-MDR1 cell monolayer. The in vivo pharmacokinetic parameters data showed OPD increased the absorption of DTX. OPD activated P-gp ATPase activity and enhanced intracellular accumulation of Rh123 in MDCK-MDR1 cells. Western blotting and qRT-PCR outcomes indicated that OPD suppressed P-gp protein expression as well as downregulated P-gp mRNA level. Thus, OPD reverse P-gp-mediated drug transport via inhibition of P-gp activity and P-gp protein expression as well as downregulation of P-gp mRNA level. Our results suggest that OPD could reverse P-gp-mediated drug resistance in tumor cells.
Bioactive coumarins from the roots and fruits of Ferulago trifida Boiss., an endemic species to Iran.[Pubmed:28954543]
Nat Prod Res. 2017 Sep 27:1-5.
Phytochemical analysis of the Ferulago trifida Boiss. from Apiaceae family led to the isolation and identification of suberosin (1), isoimperatorin (2), prantschimgin (3), oxypeucedanin (4), oxypeucedanin methanolate (5), suberenol (6), 6-hydroxymethylherniarin (7), oxypeucedanin hydrate (8), ulopterol (9), bergapten (10), xanthotoxin (11), imperatorin (12) and grandivittin (13) from chloroform extracts of the roots (1-9) and fruits (1, 2, 8, 10-13) of this species. Oxypeucedanin methanolate and suberenol demonstrated a potent antioxidant power with 268.2 +/- 5.4 and 251.2 +/- 6.2 mmol FSE/100 g, respectively, compared by BHT (267.2 +/- 4.2 mmol FSE/100 g) in FRAP method. The potent antibacterial effects were found for oxypeucedanin methanolate on S. epidermidis (IZ; 26 mm, MIC; 250 mug mL(-1)) an oxypeucedanin hydrate on K. pneumoniae (IZ: 21 mm, MIC: 250 mug mL(-1)). Moreover, suberosin showed higher preferential toxicity against MDA-MB-23 cells (IC50: 0.21 mM, SI: 5.0), in comparison with tamoxifen (IC50: 0.012 mM, SI: 2.45) in MTT assay.